CGC (Canopy Growth) Dividends Paid

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CGC Canopy Growth Corp CGC
40 GF Score
Price $1.03
GF Value $0.70
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Canopy Growth Dividends Paid?

Dividends Paid only applicable to companies reporting Cash Flow from Operations in direct method.

CGC
40GF Score
Canopy Growth Corp CGC
Dividends Paid is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Canopy Growth (CGC) Overvalued in 2026?

Based on GuruFocus' analysis, Canopy Growth stock appears to be overvalued. The current stock price of $1.03 is trading 46.4% above its estimated GF Value™ of $0.70. GuruFocus considers Canopy Growth to be Significantly Overvalued.

Key valuation signals for CGC:

  • Dividends Paid:
  • GF Value™: $0.70 vs. price of $1.03 (46.4% above fair value)
  • GF Score™: 40/100 with 4 warning signs

No single metric tells the full story. See the CGC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Canopy Growth Business Description

Other Exchanges 11L:GermanyWEED:Canada
Address 1 Hershey Drive, Smiths Falls, ON, CAN, K7A 0A8
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.
40GF Score

Get the complete analysis for CGC

Dividends Paid is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.03
Price
$0.70
GF Value